Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Freeman

Showing results (841-850 of 863) with videos related to

Pageof 87
Sort By:
Blood|May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLJad Othman, Nicola Potter, Adam Ivey, et al.
Journal of Medicinal Chemistry|December 14, 2011
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylaseKevin D Freeman-Cook, Paul Amor, Scott Bader, et al.
Blood|November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18Steven Knapper, Laura W Dillon, Malavika Babu, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 AgonistsDavid W Piotrowski, Kentaro Futatsugi, Joseph S Warmus, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2018
Reducing Door-to-Reperfusion Time for Mechanical Thrombectomy With a Multitiered Notification System for Acute Ischemic StrokeEric D Goldstein, Lynda Schnusenberg, Lesia Mooney, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2006
Potent, selective pyrimidinetrione-based inhibitors of MMP-13Lawrence A Reiter, Kevin D Freeman-Cook, Christopher S Jones, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13Kevin D Freeman-Cook, Lawrence A Reiter, Mark C Noe, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Blood Advances|May 22, 2025
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First RelapseNiek G Van Der Maas, Dimitri A Breems, Clara P W Klerk, et al.
Leukemia|August 9, 2023
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Nicola Potter, Katya Mokretar, et al.
Pageof 87

Showing results (841-850 of 863) with videos related to

Sort By:
Pageof 87
Blood|May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLJad Othman, Nicola Potter, Adam Ivey, et al.
Journal of Medicinal Chemistry|December 14, 2011
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylaseKevin D Freeman-Cook, Paul Amor, Scott Bader, et al.
Blood|November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18Steven Knapper, Laura W Dillon, Malavika Babu, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 AgonistsDavid W Piotrowski, Kentaro Futatsugi, Joseph S Warmus, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2018
Reducing Door-to-Reperfusion Time for Mechanical Thrombectomy With a Multitiered Notification System for Acute Ischemic StrokeEric D Goldstein, Lynda Schnusenberg, Lesia Mooney, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2006
Potent, selective pyrimidinetrione-based inhibitors of MMP-13Lawrence A Reiter, Kevin D Freeman-Cook, Christopher S Jones, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13Kevin D Freeman-Cook, Lawrence A Reiter, Mark C Noe, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Blood Advances|May 22, 2025
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First RelapseNiek G Van Der Maas, Dimitri A Breems, Clara P W Klerk, et al.
Leukemia|August 9, 2023
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Nicola Potter, Katya Mokretar, et al.
Pageof 87